Almac Group Reveals North American HQ Expansion Plan
Growth of CDMO's Pennsylvania facility will feature increase in cold chain storage capacity
Almac Group, a contract development and manufacturing organization (CDMO) that provides services across the drug development lifecycle to the pharma and biotech sectors, has unveiled plans for a $65 million, 100,000 square-foot expansion of clinical supply operations at the company’s North American headquarters in Souderton, PA. The capital investment plan increases clinical capacity at the facility by 60%, with additional cold and ultra-low storage and just-in-time processing capabilities. It is projected to support the industry trend towards biologics and advanced therapeutic medicinal products (ATMPs).
Almac’s expansion is expected to break ground in early 2023 and following completion, will bring the company’s North American headquarters footprint to a total of 340,000 square feet. Capacity will increase specifically in the following areas:
- 200% increase in 2-8°C storage
- 140% increase in 2-8°C packaging
- 100% increase in 20°C packaging
- 30% increase in 15-25°C storage
- 115% increase in ultra-low storage
- 100% increase in just-in-time manufacturing
“Drug development and clinical trials continue to evolve across the world, with sponsors expanding their pipelines to focus on biologics, vaccines, and advanced therapy medicinal products. ... We are committed to investing in our clients’ future challenges and are delighted that this expansion provides us with a stronger ability to service our growing customer base,” says Robert Dunlop, president and managing director, Almac Clinical Services.
